

Filed: November 13, 2014

Filed on behalf of:

Mylan Pharmaceuticals Inc.

By: Joseph M. Reisman
Jay R. Deshmukh

KNOBBE, MARTENS, OLSON & BEAR, LLP
2040 Main Street, 14th Floor
Irvine, CA 92614
Ph.: (949) 760-0404 Fax: (949) 760-9502
E-mail: BoxMylan2@knobbe.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
Patent Owners

Case No. TBD
Patent 6,335,031

PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT 6,335,031

TABLE OF CONTENTS

	Page No.
EXHIBIT LIST	vi
I. MANDATORY NOTICES	1
A. Real Party-In-Interest	1
B. Related Matters.....	1
C. Lead and Back-Up Counsel.....	3
D. Service Information	3
II. GROUNDS FOR STANDING.....	4
III. IDENTIFICATION OF CHALLENGE AND STATEMENT OF THE PRECISE RELIEF REQUESTED.....	4
IV. THRESHOLD REQUIREMENT FOR INTER PARTES REVIEW	4
V. STATEMENT OF REASONS FOR THE RELIEF REQUESTED	5
A. Level of Ordinary Skill in the Art	6
B. Claim Construction.....	7
C. Scope and Content of the Prior Art	11
1. Rivastigmine Was Being Developed for the Treatment of Alzheimer’s Disease.....	11
2. Rosin Taught the Use of Antioxidants in Compositions Comprising RA7 (Racemic Rivastigmine).....	12
3. Elmalem Taught Adding Antioxidants to a Compositions Comprising RA7 to Prevent Oxidation	13
4. Enz Taught Transdermal Rivastigmine Compositions	14
5. Ebert Taught a Transdermal Drug Delivery System For Liquid, Oxidizable Drugs.....	15

TABLE OF CONTENTS
(cont'd)

	Page No.
6. Sasaki Taught Using the Antioxidant Tocopherol to Promote Storage Stability of the Active Ingredient in Transdermal Compositions.....	17
7. The Handbook of Pharmaceutical Excipients Detailed Common Antioxidants Used in Approved Pharmaceutical Compositions.....	18
D. Ground 1: Claim 15 is Unpatentable as Anticipated by Elmalem	19
E. The Challenged Claims are Unpatentable as Obvious Over the Prior Art.....	23
1. There was Motivation to Select Rivastigmine and Modify Existing Rivastigmine Treatments	23
2. Ground 2: Claims 16 and 18 are Unpatentable as Obvious Over Elmalem and the Handbook	25
(1) No Secondary Considerations Support Non- Obviousness 28	
3. Ground 3: Claims 1, 2, 7, 15, and 18 are Obvious Over Enz and the Handbook, Optionally in View of Rosin and/or Elmalem and/or Ebert.....	31
4. Ground 4: Dependent Claims 3 and 16 are Unpatentable as Obvious Over Enz and the Handbook and/or Rosin and/or Ebert	42
5. Ground 5: The Challenged Claims Are Unpatentable As Obvious over Enz and Sasaki.....	44
VI. CONCLUSION.....	52

TABLE OF AUTHORITIES

	Page No(s).
<i>Asyst Techs., Inc. v. Emtrak, Inc.</i> , 544 F.3d 1310 (Fed. Cir. 2008)	30
<i>In re Geisler</i> , 116 F.3d 1465 (Fed. Cir. 1997)	38
<i>In re Kao</i> , 639 F.3d 1057 (Fed. Cir. 2011)	30
<i>KSR Int’l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	31
<i>MeadWestVaco Corp. v. Rexam Beauty & Closures, Inc.</i> , 731 F.3d 1258 (Fed. Cir. 2013)	29
<i>Merck & Co. v. Teva Pharms. USA, Inc.</i> , 395 F.3d 1364 (Fed. Cir. 2005)	29, 30
<i>In re Peterson</i> , 315 F.3d 1325 (Fed. Cir. 2003)	passim
<i>Pfizer, Inc. v. Apotex, Inc.</i> , 480 F.3d 1348 (Fed. Cir. 2007)	28

OTHER AUTHORITIES

35 U.S.C. § 102	passim
35 U.S.C. § 103	4
35 U.S.C. § 311	1
35 U.S.C. § 312	1
35 U.S.C. § 313	1
35 U.S.C. § 314	1, 4

TABLE OF AUTHORITIES
(cont'd)

	Page No(s).
35 U.S.C. § 315.....	1
35 U.S.C. § 316.....	1
35 U.S.C. § 317.....	1
35 U.S.C. § 318.....	1
35 U.S.C. § 319.....	1
37 C.F.R. § 42.....	1
37 C.F.R. § 42.6.....	4
37 C.F.R. § 42.10.....	1
37 C.F.R. § 42.15.....	1
37 C.F.R. § 42.100 <i>et seq.</i>	1
37 C.F.R. § 42.104.....	3

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.